*Aristo Pharma GmbH, Medical-Scientific Department, Berlin, Germany;

†Department of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Research Unit Gender in Medicine, Institute of Sexology and Sexual Medicine, Berlin, Germany;

‡Department of Psychiatry, Psychotherapy and Psychosomatics, Brandenburg Medical School, University Hospital Ruppin-Brandenburg, Neuruppin, Germany;

§Brandenburg University of Technology, Cottbus-Senftenberg and Brandenburg Medical School, Potsdam, Germany;

¶Department of Statistics, Informatics and Data Sciences, Jena University Hospital, Jena, Germany;

║Department of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany; and

**Department of Psychiatry and Psychotherapy, Fliedner Klinik Berlin, Berlin, Germany.

Correspondence: Sven Ulrich, PhD, Aristo Pharma GmbH, Medical-Scientific Department, Wallenroder Straße 8-10, Berlin 13435 Germany (e-mail: [email protected]).

S. Ulrich works for Aristo Pharma GmbH, a pharmaceutical company marketing a tranylcypromine drug product. M. Adli received research grants from Servier, Lundbeck, and Gilead; speaker honoraria from Aristo Pharma, Deutsche Bank, HRM Forum, Merz Pharma, Gilead, ViiV, MSD, Berlin Chemie, BMS, myTomorrows, Servier, and Lundbeck; and reimbursements for fees and travel expenses from Lundbeck, Aristo Pharma, and Servier. R. Ricken received an unrestricted research grant and speaker honoraria from Aristo Pharma. The other authors declare no conflicts of interest.

S. Ulrich, P. Buspavanich, R. Ricken, M. Adli have contributed equally to this work.